EUVIMEDEUVIMED entdecken
Crossref

Zolbetuximab-based chemotherapy in CLDN18.2-positive gastric cancer: real-world tumor response and early albumin kinetics

Yuki Ushimaru iD, Kazuyoshi Yamamoto, Toshihiro Kudo, Daisuke Sakai, Yoshitomo Yanagimoto, Yasunori Masuike, Kei Yamamoto, Norihiro Matsuura, Takahito Sugase iD, Takashi Kanemura, Ryota Mori, Yoshihiro Sakano und 10 weitere

Japanese Journal of Clinical Oncology · 2026

DOI: 10.1093/jjco/hyag024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2026. Verfasst von Yuki Ushimaru und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Serum Albumin, Immunoconjugates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Zolbetuximab combined with fluoropyrimidine–oxaliplatin chemotherapy has demonstrated clinical benefit in CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC). In clinical practice, however, gastrointestinal toxicity and serum albumin decline are frequently encountered during treatment, and the relationship between early albumin kinetics and antitumor efficacy remains unclear.

Methods

We conducted a single-center retrospective exploratory study of patients with unresectable or recurrent CLDN18.2-positive GC/GEJC treated with zolbetuximab-based chemotherapy between July 2024 and August 2025. Tumor response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in patients with measurable disease. The objective response rate (ORR) and early tumor shrinkage (ETS ≥20%) were assessed. Serum albumin kinetics were analyzed using baseline albumin, landmark nadir albumin measured at or immediately before the first radiological evaluation, and relative change in albumin from baseline (ΔAlb). Associations between albumin metrics and tumor response were explored using exploratory analyses, including continuous-variable modeling. Relative dose intensity and chemotherapy backbone (CAPOX vs FOLFOX) were also descriptively examined.

Results

Among 38 eligible patients, 24 had measurable disease and were evaluable for RECIST-based response. Partial response was observed in 18 patients, yielding an ORR of 75.0% (95% CI, 55.1–88.0). Early tumor shrinkage ≥20% was achieved in a proportion of evaluable cases. Baseline serum albumin showed a moderate positive correlation with landmark nadir albumin (Spearman’s ρ = 0.35, P = .030) and with ΔAlb (ρ = 0.52, P = .0007), indicating that patients with higher baseline albumin tended to experience greater absolute albumin decline. Neither landmark nadir albumin nor ΔAlb was significantly associated with the ORR or ETS. Early reductions in serum albumin were frequently observed during initial treatment cycles but did not correspond to impaired tumor response.

Conclusions

In this real-world exploratory cohort, zolbetuximab-based chemotherapy achieved objective tumor responses consistent with prior clinical trials. Early serum albumin decline was not associated with inferior tumor response. These findings suggest that early albumin decline should not be interpreted as a surrogate marker of treatment failure or reduced antitumor efficacy but rather as a treatment-related physiological change. Prospective studies are warranted to clarify the clinical implications of albumin dynamics and optimize supportive care during anti-CLDN18.2 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsSerum AlbuminImmunoconjugatesAdenocarcinomaHumansFemaleMaleRetrospective StudiesAgedMiddle AgedAdultOxaliplatinLeucovorinOrganoplatinum CompoundsFluorouracilAntibodies, MonoclonalClaudins

Stichwörter der Autor:innen

CLDN18.2albumin kineticschemotherapygastric cancergastroesophageal junction cancerzolbetuximab

Substanzen

zolbetuximabCLDN18 protein, humanSerum AlbuminImmunoconjugatesOxaliplatinLeucovorinOrganoplatinum CompoundsFluorouracilAntibodies, MonoclonalClaudins

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567, Japan.
  • Department of Medical Oncology, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka City, Osaka 541-8567, Japan.

ORCID-Profile: Yuki Ushimaru, Takahito Sugase

Zitieren

APA

Ushimaru, Y., Yamamoto, K., Kudo, T., Sakai, D., Yanagimoto, Y., Masuike, Y., Yamamoto, K., Matsuura, N., Sugase, T., Kanemura, T., Mori, R., Sakano, Y., Kitakaze, M., Kubo, M., Fukuda, Y., Komatsu, H., Miyo, M., Sueda, T., Kagawa, Y., …, & Miyata, H. (2026). Zolbetuximab-based chemotherapy in CLDN18.2-positive gastric cancer: real-world tumor response and early albumin kinetics. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyag024

Vancouver

Ushimaru Y, Yamamoto K, Kudo T, Sakai D, Yanagimoto Y, Masuike Y, et al. Zolbetuximab-based chemotherapy in CLDN18.2-positive gastric cancer: real-world tumor response and early albumin kinetics. Japanese Journal of Clinical Oncology. 2026. doi:10.1093/jjco/hyag024

BibTeX
@article{Ushimaru2026,
  author = {Ushimaru, Yuki and Yamamoto, Kazuyoshi and Kudo, Toshihiro and Sakai, Daisuke and Yanagimoto, Yoshitomo and Masuike, Yasunori and Yamamoto, Kei and Matsuura, Norihiro and Sugase, Takahito and Kanemura, Takashi and Mori, Ryota and Sakano, Yoshihiro and Kitakaze, Masatoshi and Kubo, Masahiko and Fukuda, Yasunari and Komatsu, Hisateru and Miyo, Masaaki and Sueda, Toshinori and Kagawa, Yoshinori and Gotoh, Kunihito and Kobayashi, Shogo and Miyata, Hiroshi},
  title = {Zolbetuximab-based chemotherapy in CLDN18.2-positive gastric cancer: real-world tumor response and early albumin kinetics},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1093/jjco/hyag024}
}
Kostenlos starten →